Nuclear iASPP may facilitate prostate cancer progression

Area of Science:

• Molecular Oncology
• Cancer Biology
• Prostate Cancer Research

Background:

• Prostate cancer (PCa) progression to metastasis is poorly understood.
• Loss of p63 expression is common in metastatic PCa, while p53 remains wild-type.
• Inhibitor of apoptosis-stimulating protein of p53 (iASPP) regulates both p53 and p63.

Purpose of the Study:

• To investigate the role of iASPP in prostate cancer progression.
• To determine if iASPP expression correlates with PCa invasiveness and patient outcomes.

Main Methods:

• Analysis of iASPP transgenic and knockout mouse models (iASPP(Δ8/Δ8)).
• Immunohistochemical analysis of iASPP, p53, and p63 in human PCa tissues and cell lines.
• Correlation of iASPP expression with clinical data and patient survival.

Main Results:

• iASPP deficiency reduced p63-expressing basal epithelial cells in mice.
• Nuclear and cytoplasmic iASPP expression was elevated in PCa compared to benign epithelium.
• Nuclear iASPP correlated with p53 accumulation, enrichment in metastatic cells, and association with invasive fronts.
• Increased iASPP expression predicted metastatic disease and PCa-specific mortality.

Conclusions:

• iASPP is essential for maintaining p63 expression in normal prostate basal epithelium.
• Nuclear iASPP may promote PCa progression by inactivating p53.
• iASPP serves as a potential predictive biomarker for prostate cancer progression.